Melatonin as First‑Line Sleep Aid for Elderly Post‑Cardiac Surgery Patients

Evidence Supporting Melatonin

The Society for Perioperative Assessment and Quality Improvement (SPAQI) explicitly recommends continuing melatonin perioperatively because evidence shows it is safe in the peri‑operative period and may lower delirium rates in hospitalized older adults. 1
Strength of evidence: strong guideline recommendation based on multiple peri‑operative safety studies.
A Cochrane systematic review found that pre‑operative melatonin reduces anxiety compared with placebo in adults and is as effective as midazolam for anxiolysis. 1
Strength of evidence: high‑quality meta‑analysis (Level 1 evidence).
In a prospective trial of 500 cardiac‑surgery patients, prophylactic melatonin given the night before surgery reduced postoperative delirium (8.4 % vs 20.8 %; p = 0.001). 3
Strength of evidence: randomized controlled trial with statistically significant outcome (Level 2 evidence).

The American Geriatrics Society recommends against benzodiazepines in older adults because of strong associations with dementia, fractures, and major injuries. 3
Strength of evidence: guideline based on extensive epidemiologic data (Level 1–2).
The American Academy of Sleep Medicine advises against trazodone for insomnia, noting only a ≈10‑minute reduction in sleep latency and adverse events in ~75 % of older patients (headache 30 %, somnolence 23 %). 6
Strength of evidence: guideline recommendation derived from clinical trials (Level 2).
Z‑drugs (zolpidem, eszopiclone, zaleplon) should be reserved for second‑line use because they are linked to complex sleep behaviors, falls, fractures, and next‑day cognitive impairment in elderly postoperative patients. 5
Strength of evidence: expert consensus and safety data (Level 3).
The American Academy of Sleep Medicine recommends against over‑the‑counter antihistamines (e.g., diphenhydramine, doxylamine) due to lack of efficacy and pronounced anticholinergic side‑effects (confusion, urinary retention, falls). 5
Strength of evidence: guideline based on pharmacologic safety profiles (Level 3).

The American Heart Association cites mirtazapine 7.5–15 mg at bedtime as the preferred second‑line agent for combined anxiety and insomnia in post‑cardiac‑surgery patients, noting its cardiovascular safety and dual benefit on appetite and sleep. 6
Strength of evidence: guideline recommendation (Level 2).
Low‑dose doxepin 3–6 mg reduces wake‑after‑sleep‑onset by 22–23 minutes with minimal anticholinergic activity and no abuse potential, making it suitable for elderly cardiac patients. 6
Strength of evidence: guideline based on dose‑response studies (Level 2).
Ramelteon 8 mg, a melatonin‑receptor agonist, carries no cardiovascular risk, no abuse potential, and no withdrawal symptoms, appropriate when endogenous melatonin alone is insufficient. 6
Strength of evidence: guideline recommendation (Level 2).
If short‑term rescue is needed, age‑adjusted zolpidem 5 mg can shorten sleep‑onset latency by ≈25 minutes, but must be used cautiously because of fall and cognitive‑impairment risk. 6
Strength of evidence: guideline (Level 3) with cautionary note.
Zaleplon 5 mg, with an ultra‑short half‑life, produces minimal residual sedation and is appropriate for middle‑of‑night awakenings when ≥4 hours remain before planned awakening. 6
Strength of evidence: guideline (Level 3).

Cognitive Behavioral Therapy for Insomnia (CBT‑I) should be initiated immediately alongside any medication, as it provides superior long‑term efficacy and sustained benefits after drug discontinuation. 6
Strength of evidence: guideline (Level 1).
The American Heart Association mandates CBT‑I before any pharmacologic intervention for cardiovascular patients with insomnia. 6
Strength of evidence: strong guideline recommendation.
Noise‑ and light‑reduction strategies (earplugs, eye‑shades) improve sleep quality and lower delirium rates in ICU patients, including those after cardiac surgery. 7
Strength of evidence: randomized trial (Level 2).
Applying earplugs (with or without eye‑shades) on the first postoperative ICU night maintains sleep quality at pre‑operative levels and should be offered to all patients. 7
Strength of evidence: randomized trial (Level 2).

Reassess sleep outcomes, daytime functioning, and adverse effects (e.g., morning sedation, cognitive impairment, cardiac symptoms) after 1–2 weeks of therapy. 6
Strength of evidence: guideline (Level 3).
Use the lowest effective dose for the shortest necessary duration, with ongoing CBT‑I to facilitate eventual tapering of medication. 6
Strength of evidence: guideline (Level 3).
Screen for and address underlying contributors to insomnia—post‑operative pain, medication side‑effects (β‑blockers, diuretics), and sleep‑disordered breathing—which are common after cardiac surgery. 6
Strength of evidence: expert consensus (Level 3).

Sertraline is the preferred SSRI for anxiety in post‑cardiac‑surgery patients because it has a lower propensity for QTc prolongation compared with citalopram or escitalopram. 6
Strength of evidence: guideline (Level 2).
Avoid combining multiple sedating agents (e.g., benzodiazepine + Z‑drug + sedating antidepressant) as this markedly increases risk of respiratory depression, cognitive impairment, and falls. 6
Strength of evidence: expert consensus (Level 3).
A low‑dose dexmedetomidine infusion in the ICU from admission until 08:00 h on postoperative day 1 reduced delirium risk (9 % vs 23 %; p < 0.0001) and improved sleep quality in cardiac‑surgery patients, though this is limited to ICU settings. 3
Strength of evidence: randomized controlled trial (Level 2).